2021
Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients.
Sharpe J, Schnell P, Knopp M, Binzel K, Magyer M, Cherian M, Gatti-Mays M, Pariser A, Wesolowski R, Sardesai S, VanDeusen J, Stover D, Ramaswamy B, Williams N, DeVries A, Shinde N, Orchard T, Lustberg M. Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients. Journal Of Clinical Oncology 2021, 39: e12528-e12528. DOI: 10.1200/jco.2021.39.15_suppl.e12528.Peer-Reviewed Original ResearchPET/CT imagingPET/CTCytokine levelsMicroglial activationCT imagingF-fluorodeoxyglucoseDouble-blinded randomized placebo-controlled trialBlinded randomized placebo-controlled trialChemotherapy-induced cognitive changesRandomized placebo-controlled trialCognitive functionPlacebo-controlled trialInflammatory cytokine levelsBreast cancer patientsCognitive changesCT brain imagingAC therapyDaily minocyclinePotent mitigatorNeoadjuvant chemotherapyPlacebo groupInflammatory markersInflammatory changesMedian ageMinocycline groupAssociation of pathological complete response rates and TILs in triple-negative breast cancer patients.
Kassem M, Goldstein D, Schnell P, Grimm M, Quiroga D, Miah A, Vargo C, Shinde N, Michael B, Pariser A, Gatti-Mays M, VanDeusen J, Williams N, Stover D, Sardesai S, Wesolowski R, Lustberg M, Ramaswamy B, Tozbikian G, Cherian M. Association of pathological complete response rates and TILs in triple-negative breast cancer patients. Journal Of Clinical Oncology 2021, 39: e12596-e12596. DOI: 10.1200/jco.2021.39.15_suppl.e12596.Peer-Reviewed Original ResearchTriple-negative breast cancerTumor-infiltrating lymphocytesInternational TILs Working GroupPathological complete response rateComplete response rateNeoadjuvant chemotherapyLong-term prognosisTNBC patientsBreast cancerAssociation of TILsResponse rateHigh distant recurrence rateOhio State University Comprehensive Cancer CenterTriple-negative breast cancer patientsSingle-institution retrospective analysisHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Residual cancer burden indexRates of breastDistant recurrence ratesPreoperative systemic therapyGrowth factor receptor 2Majority of patientsInvasive ductal cancerBreast cancer patients
2017
Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer.
Stiff A, McQuinn C, Wesolowski R, Lustberg M, Reinbolt R, VanDeusen J, Sardesai S, Williams N, Noonan A, Dewani S, Ramaswamy B, Carson W. Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer. Journal Of Clinical Oncology 2017, 35: e12126-e12126. DOI: 10.1200/jco.2017.35.15_suppl.e12126.Peer-Reviewed Original ResearchNeo-adjuvant chemotherapyCD8 T cellsCD4 T cellsMore CD8 T cellsT cellsBreast cancerReceptor expressionCheckpoint inhibitorsCheckpoint expressionComplete pathologic response rateMore CD4 T cellsHormone receptorsPathologic response rateClinical stage IOperable breast cancerImmune checkpoint expressionReceptor expression changesBC subgroupsNeoadjuvant chemotherapyClinical responseProspective trialImmune checkpointsMedian agePD-1CTLA-4
2015
Neoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials
Hicks M, Macrae E, Abdel‐Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Neoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials. The Oncologist 2015, 20: 337-343. PMID: 25732265, PMCID: PMC4391765, DOI: 10.1634/theoncologist.2014-0334.Peer-Reviewed Original ResearchConceptsAddition of lapatinibHER2-positive breast cancerNeoadjuvant chemotherapyBreast cancerLymph nodesClinical trialsEarly-stage HER2-positive breast cancerSan Antonio Breast Cancer SymposiumPathologic complete response rateEarly-stage breast cancerResidual invasive cancerResidual invasive carcinomaComplete response rateOperable breast cancerAxillary lymph nodesPathologic complete responseProspective clinical trialsStage breast cancerRates of pCRDual HER2NAC armProspective RCTsCancer SymposiumPCR rateComplete response
2013
A phase I study of neoadjuvant chemotherapy (NCT) with the gamma secretase (GS) inhibitor RO4929097 in combination with paclitaxel (P) and carboplatin (C) in women with triple-negative breast cancer (TNBC).
Mrozek E, Wesolowski R, Lustberg M, Layman R, Ling Y, Schaaf L, Phelps M, Ivy S, Grever M, Shapiro C. A phase I study of neoadjuvant chemotherapy (NCT) with the gamma secretase (GS) inhibitor RO4929097 in combination with paclitaxel (P) and carboplatin (C) in women with triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2013, 31: 1043-1043. DOI: 10.1200/jco.2013.31.15_suppl.1043.Peer-Reviewed Original ResearchTriple-negative breast cancerMaximum-tolerated doseNon-hematologic toxicitiesNeoadjuvant chemotherapyAUC 5G4 neutropeniaDay 1Gamma secretase inhibitor RO4929097Cycles of NACGrade 4 thrombocytopeniaComplete pathologic responseTreatment-related toxicityMinimal residual cancerMinimal residual diseaseLC-MS/MS assaysAUC 6G3 anemiaG3 fatigueG3 neutropeniaG3 thrombocytopeniaG4 thrombocytopeniaStarting dosePathologic responseResidual cancerOral inhibitor
2012
Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer
Yang X, Mrozek E, Lustberg M, Jia G, Sammet S, Sammet C, Shapiro C, Knopp M. Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer. Magnetic Resonance Imaging 2012, 30: 1059-1067. PMID: 22884756, PMCID: PMC3645932, DOI: 10.1016/j.mri.2012.04.026.Peer-Reviewed Original ResearchConceptsPotential imaging markerPathologic responseBreast cancerTumor heterogeneityImaging markerHER-2 negative breast cancerImaging biomarkersVolumetric biomarkersCombination neoadjuvant chemotherapyCurrent imaging studiesGood predictive biomarkerNegative breast cancerTherapeutic response assessmentNovel imaging biomarkersNeoadjuvant chemotherapyRetrospective studyPredictive biomarkersNovel biomarkersResponse assessmentHeterogeneous diseaseEarly changesImaging studiesBiomarkersCancerCellular composition
2010
Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI).
Mrozek E, Lustberg M, Knopp M, Spigos D, Yang X, Houton L, Ramaswamy B, Layman R, Povoski S, Agnese D. Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI). Journal Of Clinical Oncology 2010, 28: 604-604. DOI: 10.1200/jco.2010.28.15_suppl.604.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyBreast cancerDynamic contrast magnetic resonance imagingWeekly nanoparticle albumin-bound paclitaxelNanoparticle albumin-bound paclitaxelClinical stage IIPhase II trialAlbumin-bound paclitaxelContrast magnetic resonance imagingMagnetic resonance imagingII trialResonance imagingStage IIBevacizumabCarboplatinChemotherapyCancerPaclitaxelTrials